#BEGIN_DRUGCARD DB03754

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
9754

# Chemical_Formula:
C4H12NO3

# Chemical_IUPAC_Name:
1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)

# Dosage_Forms:
Not Available

# Drug_Category:
Buffers
Excipients

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Tris(Hydroxymethyl)Aminomethane

# HET_ID:
TMN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2/p+1

# InChI_Key:
InChIKey=LENZDBCJOHFCAS-UHFFFAOYSA-O

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3754

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
122.143

# Molecular_Weight_Mono:
122.081718255

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1PBT

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.5

# Predicted_LogS:
0.37

# Predicted_Water_Solubility:
3.70e+02 g/l

# Primary_Accession_No:
DB03754

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
3777159

# PubChem_Substance_ID:
46506027

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03072

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[NH3+]C(CO)(CO)CO

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:35 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
J04423

# Drug_Target_10_GenBank_ID_Protein:
145425

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
bioB

# Drug_Target_10_Gene_Sequence:
>1041 bp
ATGGCTCACCGCCCACGCTGGACATTGTCGCAAGTCACAGAATTATTTGAAAAACCGTTG
CTGGATCTGCTGTTTGAAGCGCAGCAGGTGCATCGCCAGCATTTCGATCCTCGTCAGGTG
CAGGTCAGCACGTTGCTGTCGATTAAGACCGGAGCTTGTCCGGAAGATTGCAAATACTGC
CCGCAAACGTCGCGCTACAAAACCGGGCTGGAAGCCGAGCGGTTGATGGAAGTTGAACAG
GTGCTGGAGTCGGCGCGCAAAGCGAAAGCGGCAGGATCGACGCGCTTCTGTATGGGCGCG
GCGTGGAAGAATCCCCACGAACGCGATATGCCGTACCTGGAACAAATGGTGCAGGGGGTA
AAAGCGATGGGGCTGGAGGCGTGTATGACGCTGGGCACGTTGAGTGAATCTCAGGCGCAG
CGCCTCGCGAACGCCGGGCTGGATTACTACAACCACAACCTGGACACCTCGCCGGAGTTT
TACGGCAATATCATCACCACACGCACTTATCAGGAACGCCTCGATACGCTGGAAAAAGTG
CGCGATGCCGGGATCAAAGTCTGTTCTGGCGGCATTGTGGGCTTAGGCGAAACGGTAAAA
GATCGCGCCGGATTATTGCTGCAACTGGCAAACCTGCCGACGCCGCCGGAAAGCGTGCCA
ATCAACATGCTGGTGAAGGTGAAAGGCACGCCGCTTGCCGATAACGATGATGTCGATGCC
TTTGATTTTATTCGCACCATTGCGGTCGCGCGGATCATGATGCCAACCTCTTACGTGCGC
CTTTCTGCCGGACGCGAGCAGATGAACGAACAGACTCAGGCGATGTGCTTTATGGCAGGC
GCAAACTCGATTTTCTACGGTTGCAAACTGCTGACCACGCCGAATCCGGAAGAAGATAAA
GACCTGCAACTGTTCCGCAAACTGGGGCTAAATCCGCAGCAAACTGCCGTGCTGGCAGGG
GATAACGAACAACAGCAACGTCTTGAACAGGCGCTGATGACCCCGGACACCGACGAATAT
TACAACGCGGCAGCATTATGA

# Drug_Target_10_General_Function:
Coenzyme transport and metabolism

# Drug_Target_10_General_References:
11686925	Farh L, Hwang SY, Steinrauf L, Chiang HJ, Shiuan D: Structure-function studies of Escherichia coli biotin synthase via a chemical modification and site-directed mutagenesis approach. J Biochem (Tokyo). 2001 Nov;130(5):627-35.
11834738	Ollagnier-de Choudens S, Sanakis Y, Hewitson KS, Roach P, Munck E, Fontecave M: Reductive cleavage of S-adenosylmethionine by biotin synthase from Escherichia coli. J Biol Chem. 2002 Apr 19;277(16):13449-54. Epub 2002 Feb 7.
11862544	Hewitson KS, Ollagnier-de Choudens S, Sanakis Y, Shaw NM, Baldwin JE, Munck E, Roach PL, Fontecave M: The iron-sulfur center of biotin synthase: site-directed mutants. J Biol Inorg Chem. 2002 Jan;7(1-2):83-93. Epub 2001 Jul 11.
12440894	Cosper MM, Jameson GN, Davydov R, Eidsness MK, Hoffman BM, Huynh BH, Johnson MK: The [4Fe-4S](2+) cluster in reconstituted biotin synthase binds S-adenosyl-L-methionine. J Am Chem Soc. 2002 Nov 27;124(47):14006-7.
12824504	Cosper MM, Cosper NJ, Hong W, Shokes JE, Broderick WE, Broderick JB, Johnson MK, Scott RA: Structural studies of the interaction of S-adenosylmethionine with the [4Fe-4S] clusters in biotin synthase and pyruvate formate-lyase activating enzyme. Protein Sci. 2003 Jul;12(7):1573-7.
3058702	Otsuka AJ, Buoncristiani MR, Howard PK, Flamm J, Johnson C, Yamamoto R, Uchida K, Cook C, Ruppert J, Matsuzaki J: The Escherichia coli biotin biosynthetic enzyme sequences predicted from the nucleotide sequence of the bio operon. J Biol Chem. 1988 Dec 25;263(36):19577-85.
8142361	Sanyal I, Cohen G, Flint DH: Biotin synthase: purification, characterization as a [2Fe-2S]cluster protein, and in vitro activity of the Escherichia coli bioB gene product. Biochemistry. 1994 Mar 29;33(12):3625-31.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
3164

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
38649

# Drug_Target_10_Name:
Biotin synthase

# Drug_Target_10_Number_of_Residues:
346

# Drug_Target_10_PDB_ID:
1R30

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF04055	Radical_SAM
PF06968	BATS

# Drug_Target_10_Protein_Sequence:
>Biotin synthase
MAHRPRWTLSQVTELFEKPLLDLLFEAQQVHRQHFDPRQVQVSTLLSIKTGACPEDCKYC
PQSSRYKTGLEAERLMEVEQVLESARKAKAAGSTRFCMGAAWKNPHERDMPYLEQMVQGV
KAMGLEACMTLGTLSESQAQRLANAGLDYYNHNLDTSPEFYGNIITTRTYQERLDTLEKV
RDAGIKVCSGGIVGLGETVKDRAGLLLQLANLPTPPESVPINMLVKVKGTPLADNDDVDA
FDFIRTIAVARIMMPTSYVRLSAGREQMNEQTQAMCFMAGANSIFYGCKLLTTPNPEEDK
DLQLFRKLGLNPQQTAVLAGDNEQQQRLEQALMTPDTDEYYNAAAL

# Drug_Target_10_Reaction:
dethiobiotin + sulfur + 2 S-adenosyl-L-methionine = biotin + 2 L-methionine + 2 5'-deoxyadenosine

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Dethiobiotin + sulfur + 2 S-adenosyl-L- methionine = biotin + 2 L-methionine + 2 5'-deoxyadenosine

# Drug_Target_10_SwissProt_ID:
P12996

# Drug_Target_10_SwissProt_Name:
BIOB_ECOLI

# Drug_Target_10_Synonyms:
Biotin synthetase
EC 2.8.1.6

# Drug_Target_10_Theoretical_pI:
5.13

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Secreted protein. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
VEGF

# Drug_Target_11_GenBank_ID_Gene:
M32977

# Drug_Target_11_GenBank_ID_Protein:
181971

# Drug_Target_11_GeneCard_ID:
VEGF

# Drug_Target_11_Gene_Name:
VEGFA

# Drug_Target_11_Gene_Sequence:
>699 bp
ATGAACTTTCTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCTGCTCTACCTCCACCAT
GCCAAGTGGTCCCAGGCTGCACCCATGGCAGAAGGAGGAGGGCAGAATCATCACGAAGTG
GTGAAGTTCATGGATGTCTATCAGCGCAGCTACTGCCATCCAATCGAGACCCTGGTGGAC
ATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAGCCATCCTGTGTGCCCCTG
ATGCGATGCGGGGGCTGCTGCAATGACGAGGGCCTGGAGTGTGTGCCCACTGAGGAGTCC
AACATCACCATGCAGATTATGCGGATCAAACCTCACCAAGGCCAGCACATAGGAGAGATG
AGCTTCCTACAGCACAACAAATGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAA
AAAAAATCAGTTCGAGGAAAGGGAAAGGGGCAAAAACGAAAGCGCAAGAAATCCCGGTAT
AAGTCCTGGAGCGTGTACGTTGGTGCCCGCTGCTGTCTAATGCCCTGGAGCCTCCCTGGC
CCCCATCCCTGTGGGCCTTGCTCAGAGCGGAGAAAGCATTTGTTTGTACAAGATCCGCAG
ACGTGTAAATGTTCCTGCAAAAACACAGACTCGCGTTGCAAGGCGAGGCAGCTTGAGTTA
AACGAACGTACTTGCAGATGTGACAAGCCGAGGCGGTGA

# Drug_Target_11_General_Function:
Involved in growth factor activity

# Drug_Target_11_General_References:
10067980	Jingjing L, Xue Y, Agarwal N, Roque RS: Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1999 Mar;40(3):752-9.
10464055	Whittle C, Gillespie K, Harrison R, Mathieson PW, Harper SJ: Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin Sci (Lond). 1999 Sep;97(3):303-12.
11427521	Murphy JF, Fitzgerald DJ: Vascular endothelial growth factor induces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor. FASEB J. 2001 Jul;15(9):1667-9.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
1567395	Weindel K, Marme D, Weich HA: AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. Biochem Biophys Res Commun. 1992 Mar 31;183(3):1167-74.
1711045	Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991 Jun 25;266(18):11947-54.
1791831	Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991 Dec;5(12):1806-14.
2479986	Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989 Dec 8;246(4935):1306-9.
2479987	Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989 Dec 8;246(4935):1309-12.
2584205	Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL, Leimgruber R, Feder J: Human vascular permeability factor. Isolation from U937 cells. J Biol Chem. 1989 Nov 25;264(33):20017-24.
7678805	Fiebich BL, Jager B, Schollmann C, Weindel K, Wilting J, Kochs G, Marme D, Hug H, Weich HA: Synthesis and assembly of functionally active human vascular endothelial growth factor homodimers in insect cells. Eur J Biochem. 1993 Jan 15;211(1-2):19-26.
9054410	Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G: VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem. 1997 Mar 14;272(11):7151-8.
9207067	Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM: Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7192-7.
9336848	Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA: 1H, 13C, and 15N backbone assignment and secondary structure of the receptor-binding domain of vascular endothelial growth factor. Protein Sci. 1997 Oct;6(10):2250-60.
9351807	Muller YA, Christinger HW, Keyt BA, de Vos AM: The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure. 1997 Oct 15;5(10):1325-38.
9450968	Claffey KP, Shih SC, Mullen A, Dziennis S, Cusick JL, Abrams KR, Lee SW, Detmar M: Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA stability. Mol Biol Cell. 1998 Feb;9(2):469-81.
9634701	Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA: Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure. 1998 May 15;6(5):637-48.
9878851	Lei J, Jiang A, Pei D: Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta. 1998 Dec 22;1443(3):400-6.
9922142	Wiesmann C, Christinger HW, Cochran AG, Cunningham BC, Fairbrother WJ, Keenan CJ, Meng G, de Vos AM: Crystal structure of the complex between VEGF and a receptor-blocking peptide. Biochemistry. 1998 Dec 22;37(51):17765-72.

# Drug_Target_11_HGNC_ID:
HGNC:12680

# Drug_Target_11_HPRD_ID:
01889

# Drug_Target_11_ID:
183

# Drug_Target_11_Locus:
6p12

# Drug_Target_11_Molecular_Weight:
27043

# Drug_Target_11_Name:
Vascular endothelial growth factor A

# Drug_Target_11_Number_of_Residues:
232

# Drug_Target_11_PDB_ID:
1TZI

# Drug_Target_11_Pathway:
Bevacizumab Pathway	SMP00420
Vatalanib Pathway	SMP00421

# Drug_Target_11_Pfam_Domain_Function:
PF00341	PDGF

# Drug_Target_11_Protein_Sequence:
>Vascular endothelial growth factor A precursor
MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVD
IFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEM
SFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPG
PHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
1-26

# Drug_Target_11_Specific_Function:
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis, and induces permeabilization of blood vessels. Binds to the VEGFR1/Flt-1 and VEGFR2/Kdr receptors, heparan sulfate and heparin. Neuropilin-1 binds isoforms VEGF-165 and VEGF-145

# Drug_Target_11_SwissProt_ID:
P15692

# Drug_Target_11_SwissProt_Name:
VEGFA_HUMAN

# Drug_Target_11_Synonyms:
VEGF-A
VPF
Vascular endothelial growth factor A precursor
Vascular permeability factor

# Drug_Target_11_Theoretical_pI:
9.08

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Cytoplasmic

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
AE000512

# Drug_Target_12_GenBank_ID_Protein:
4981702

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
pgl

# Drug_Target_12_Gene_Sequence:
>663 bp
TTATTTTCCCACAAACCAGACGGTTTTCTCTTTGCCTCTCACGAAGTAAGCGGGAAGTGG
TGTATCTTTTAAGATCTCCGTTAGTCTGTTTATCTTTTCTTTTCCCCTGATGAGAAAGAG
CACGTACAGTGATGTGTTCAGTGCACGAAACGTCAGGGTGACTCTGGGAACCTTAGGGTC
ACCGGAAGGATCTGTGAAAGTCACAAGGTTGTCTTTATTTCCCGTTTCCAAGTCGAATAT
GGACGCGACATGGCCATCGGGACCCATTCCAAGAATAGCGAGGTCGAACTGGTCAGTAGC
TGATCTTATTTCCCTCTCATATTTCTCGCAGGCTTTTTCAATAGGAAGAGAAGTGTCAAC
GTAGTGAACATTACCGGAAGGGATCTTTGCTCTGCTGAAAAGAACCTCGTTTATGTTCCT
GAAATTGCTTTGATCTGAGTCGAGGGGCACGTACCGCTCGTCGCTCAAAAAGAAGTGGAT
GCGATTCCATGGGAACTTCTGTTCTGCCAGTTTCTCATAAACGGGAAGTGGGGTTCTCCC
GCCGGCGAGAACGACGAAGATCTTATCCTTTTCCTCGAGAAGTTTTTCCATCTTTGTGCG
AATTTTCTCGACTACAAAATCAACGTACCCATCTTCGAGCAGGTATATCACAGTTTTCTC
CAT

# Drug_Target_12_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_12_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
3583

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
25325

# Drug_Target_12_Name:
6-phosphogluconolactonase

# Drug_Target_12_Number_of_Residues:
220

# Drug_Target_12_PDB_ID:
1VL1

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF01182	Glucosamine_iso

# Drug_Target_12_Protein_Sequence:
>6-phosphogluconolactonase
MEKTVIYLLEDGYVDFVVEKIRTKMEKLLEEKDKIFVVLAGGRTPLPVYEKLAEQKFPWN
RIHFFLSDERYVPLDSDQSNFRNINEVLFSRAKIPSGNVHYVDTSLPIEKACEKYEREIR
SATDQFDLAILGMGPDGHVASIFDLETGNKDNLVTFTDPSGDPKVPRVTLTFRALNTSLY
VLFLIRGKEKINRLTEILKDTPLPAYFVRGKEKTVWFVGK

# Drug_Target_12_Reaction:
6-phospho-D-glucono-1,5-lactone + H2O = 6-phospho-D-gluconate

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Hydrolysis of 6-phosphogluconolactone to 6- phosphogluconate

# Drug_Target_12_SwissProt_ID:
Q9X0N8

# Drug_Target_12_SwissProt_Name:
6PGL_THEMA

# Drug_Target_12_Synonyms:
6PGL
EC 3.1.1.31

# Drug_Target_12_Theoretical_pI:
6.81

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Not Available

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
Not Available

# Drug_Target_13_GenBank_ID_Gene:
Not Available

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
DCN

# Drug_Target_13_Gene_Sequence:
Not Available

# Drug_Target_13_General_Function:
Not Available

# Drug_Target_13_General_References:
Not Available

# Drug_Target_13_HGNC_ID:
Not Available

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
7020

# Drug_Target_13_Locus:
Not Available

# Drug_Target_13_Molecular_Weight:
Not Available

# Drug_Target_13_Name:
Decorin

# Drug_Target_13_Number_of_Residues:
0

# Drug_Target_13_PDB_ID:
Not Available

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
Not Available

# Drug_Target_13_Protein_Sequence:
Not Available

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
Not Available

# Drug_Target_13_Specific_Function:
Not Available

# Drug_Target_13_SwissProt_ID:
P07585

# Drug_Target_13_SwissProt_Name:
PGS2_HUMAN

# Drug_Target_13_Synonyms:
Not Available

# Drug_Target_13_Theoretical_pI:
Not Available

# Drug_Target_13_Transmembrane_Regions:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M13812

# Drug_Target_1_GenBank_ID_Protein:
153695

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
lytA

# Drug_Target_1_Gene_Sequence:
>957 bp
ATGGAAATTAATGTGAGTAAATTAAGAACAGATTTGCCTCAAGTCGGCGTGCAACCATAT
AGGCAAGTACACGCACACTCAACTGGGAATCCGCATTCAACCGTACAGAATGAAGCGGAT
TATCACTGGCGGAAAGACCCAGAATTAGGTTTTTTCTCGCACATTGTTGGGAACGGTTGC
ATCATGCAGGTAGGACCTGTTGATAATGGTGCCTGGGACGTTGGGGGCGGTTGGAATGCT
GAGACCTATGCAGCGGTTGAACTGATTGAAAGCCATTCAACCAAAGAAGAGTTCATGACG
GACTACCGCCTTTATATCGAACTCTTACGCAATCTAGCAGATGAAGCAGGTTTGCCGAAA
ACGCTTGATACAGGGAGTTTAGCTGGAATTAAAACGCACGAGTATTGCACGAATAACCAA
CCAAACAACCACTCAGACCACGTTGACCCTTATCCATATCTTGCTAAATGGGGCATTAGC
CGTGAGCAGTTTAAGCATGATATTGAGAACGGCTTGACGATTGAAACAGGCTGGCAGAAG
AATGACACTGGCTACTGGTACGTACATTCAGACGGCTCTTATCCAAAAGACAAGTTTGAG
AAAATCAATGGCACTTGGTACTACTTTGACAGTTCAGGCTATATGCTTGCAGACCGCTGG
AGGAAGCACACAGACGGCAACTGGTACTGGTTCGACAACTCAGGCGAAATGGCTACAGGC
TGGAAGAAAATCGCTGATAAGTGGTACTATTTCAACGAAGAAGGTGCCATGAAGACAGGC
TGGGTCAAGTACAAGGACACTTGGTACTACTTAGACGCTAAAGAAGGCGCCATGGTATCA
AATGCCTTTATCCAGTCAGCGGACGGAACAGGCTGGTACTACCTCAAACCAGACGGAACA
CTGGCAGACAGGCCAGAATTCACAGTAGAGCCAGATGGCTTGATTACAGTAAAATAA

# Drug_Target_1_General_Function:
Involved in N-acetylmuramoyl-L-alanine amidase activity

# Drug_Target_1_General_References:
11463916	Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001 Jul 20;293(5529):498-506.
2875013	Garcia P, Garcia JL, Garcia E, Lopez R: Nucleotide sequence and expression of the pneumococcal autolysin gene from its own promoter in Escherichia coli. Gene. 1986;43(3):265-72.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3259

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
36545

# Drug_Target_1_Name:
Autolysin

# Drug_Target_1_Number_of_Residues:
318

# Drug_Target_1_PDB_ID:
1GVM

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01473	CW_binding_1
PF01510	Amidase_2

# Drug_Target_1_Protein_Sequence:
>Autolysin
MEINVSKLRTDLPQVGVQPYRQVHAHSTGNPHSTVQNEADYHWRKDPELGFFSHIVGNGC
IMQVGPVDNGAWDVGGGWNAETYAAVELIESHSTKEEFMTDYRLYIELLRNLADEAGLPK
TLDTGSLAGIKTHEYCTNNQPNNHSDHVDPYPYLAKWGISREQFKHDIENGLTIETGWQK
NDTGYWYVHSDGSYPKDKFEKINGTWYYFDSSGYMLADRWRKHTDGNWYWFDNSGEMATG
WKKIADKWYYFNEEGAMKTGWVKYKDTWYYLDAKEGAMVSNAFIQSADGTGWYYLKPDGT
LADKPEFTVEPDGLITVK

# Drug_Target_1_Reaction:
Hydrolyses the link between N-acetylmuramoyl residues and L-amino acid residues in certain cell-wall glycopeptides ALL_REAC (other) R04112 REFERENCE 1 [PMID:5777325] AUTHORS Ghuysen JM, Dierickx L, Coyette J, Leyh-Bouille M, Guinand M, Campbell JN. TITLE An improved technique for the preparation of Streptomyces peptidases and N-acetylmuramyl-l-alanine amidase active on bacterial wall peptidoglycans. JOURNAL Biochemistry. 8 (1969) 213-22. ORGANISM Streptomyces aureus REFERENCE 2 [PMID:809432] AUTHORS Herbold DR, Glaser L. TITLE Interaction of N-acetylmuramic acid L-alanine amidase with cell wall polymers. JOURNAL J. Biol. Chem. 250 (1975) 7231-8. REFERENCE 3 [PMID:803507] AUTHORS Herbold DR, Glaser L. TITLE Bacillus subtilis N-acetylmuramic acid L-alanine amidase. JOURNAL J. Biol. Chem. 250 (1975) 1676-82. ORGANISM Bacillus subtilis [GN:bsu] REFERENCE 4 [PMID:6126517] AUTHORS Ward JB, Curtis CA, Taylor C, Buxton RS. TITLE Purification and characterization of two phage PBSX-induced lytic enzymes of Bacillus subtilis 168: an N-acetylmuramoyl-L-alanine amidase and an N-acetylmuramidase. JOURNAL J. Gen. Microbiol. 128 (1982) 1171-8. ORGANISM Bacillus subtilis [GN:bsu]

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Autolysins are involved in some important biological processes such as cell separation, cell-wall turnover, competence for genetic transformation, formation of the flagella and sporulation. Autolysin strictly depends on the presence of choline-containing cell walls for activity

# Drug_Target_1_SwissProt_ID:
P06653

# Drug_Target_1_SwissProt_Name:
ALYS_STRPN

# Drug_Target_1_Synonyms:
Cell wall hydrolase
EC 3.5.1.28
Mucopeptide aminohydrolase
Murein hydrolase
N-acetylmuramoyl-L-alanine amidase

# Drug_Target_1_Theoretical_pI:
4.99

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Periplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
U05988

# Drug_Target_2_GenBank_ID_Protein:
516878

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
cc4

# Drug_Target_2_Gene_Sequence:
>633 bp
ATGAACAAAGTACTCGTGAGTCTGCTGTTGACCCTTGGCATCACCGGTATGGCCCACGCG
GCTGGAGACGCCGAAGCTGGTCAGGGCAAAGTTGCAGTGTGTGGTGCGTGCCACGGTGTC
GATGGCAACAGCCCGGCGCCGAATTTCCCGAAACTGGCTGGCCAGGGTGAGCGTTACCTG
CTCAAGCAACTGCAGGACATCAAGGCTGGCAGCACACCGGGTGCCCCGGAAGGCGTAGGT
CGCAAGGTGTTGGAAATGACCGGCATGCTGGACCCGCTGAGTGATCAGGATCTGGAAGAC
ATCGCCGCCTACTTCTCAAGCCAGAAGGGCAGTGTTGGTTACGCCGATCCGGCTCTGGCA
AAGCAGGGCGAGAAACTGTTCCGTGGTGGCAAGCTCGATCAGGGCATGCCGGCGTGCACC
GGTTGCCACGCACCCAACGGCGTCGGTAACGACCTGGCTGGCTTCCCCAAGCTGGGTGGG
CAGCACGCGGCGTACACCGCCAAGCAGCTGACCGACTTCCGCGAAGGCAATCGCACCAAC
GACGGCGACACCATGATCATGCGTGGCGTCGCCGCCAAGCTGAGCAACAAGGACATCGAA
GCGCTGTCCAGCTACATCCAGGGCCTGCACTGA

# Drug_Target_2_General_Function:
Energy production and conversion

# Drug_Target_2_General_References:
8026750	Christensen HE: Cloning and characterisation of the gene encoding cytochrome c4 from Pseudomonas stutzeri. Gene. 1994 Jun 24;144(1):139-40.
9032080	Kadziola A, Larsen S: Crystal structure of the dihaem cytochrome c4 from Pseudomonas stutzeri determined at 2.2A resolution. Structure. 1997 Feb 15;5(2):203-16.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3221

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
21742

# Drug_Target_2_Name:
Cytochrome c4

# Drug_Target_2_Number_of_Residues:
210

# Drug_Target_2_PDB_ID:
1M70

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00034	Cytochrom_C

# Drug_Target_2_Protein_Sequence:
>Cytochrome c4 precursor
MNKVLVSLLLTLGITGMAHAAGDAEAGQGKVAVCGACHGVDGNSPAPNFPKLAGQGERYL
LKQLQDIKAGSTPGAPEGVGRKVLEMTGMLDPLSDQDLEDIAAYFSSQKGSVGYADPALA
KQGEKLFRGGKLDQGMPACTGCHAPNGVGNDLAGFPKLGGQHAAYTAKQLTDFREGNRTN
DGDTMIMRGVAAKLSNKDIEALSSYIQGLH

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-20

# Drug_Target_2_Specific_Function:
Diheme, high potential cytochrome c believed to be an intermediate electron donor to terminal oxidation systems

# Drug_Target_2_SwissProt_ID:
Q52369

# Drug_Target_2_SwissProt_Name:
CYC4_PSEST

# Drug_Target_2_Synonyms:
Cytochrome c4 precursor

# Drug_Target_2_Theoretical_pI:
6.67

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Intracytoplasmic membrane
single-pass type II membrane protein. Processed form:Secreted protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
CANT1

# Drug_Target_3_GenBank_ID_Gene:
AF328554

# Drug_Target_3_GenBank_ID_Protein:
22218108

# Drug_Target_3_GeneCard_ID:
CANT1

# Drug_Target_3_Gene_Name:
CANT1

# Drug_Target_3_Gene_Sequence:
>1116 bp
ATGACCAAGGCCGCGGACCCCCGCTTCCGCCCCCGCTGGAAGGTGATCCTGACGTTCTTT
GTGGGTGCTGCCATCCTCTGGCTGCTCTGCTCCCACCGCCCGGCCCCCGGCAGGCCCCCC
ACCCACAATGCACACAACTGGAGGCTCGGCCAGGCGCCCGCCAACTGGTACAATGACACC
TACCCCCTGTCTCCCCCACAAAGGACACCGGCTGGGATTCGGTATCGAATCGCAGTTATC
GCAGACCTGGACACAGAGTCAAGGGCCCAAGAGGAAAACACCTGGTTCAGTTACCTGAAA
AAGGGCTACCTGACCCTGTCAGACAGTGGGGACAAGGTGGCCGTGGAATGGGACAAAGAC
CATGGGGTCCTGGAGTCCCACCTGGCGGAGAAGGGGAGAGGCATGGAGCTATCCGACCTG
ATTGTTTTCAATGGGAAACTCTACTCCGTGGATGACCGGACGGGGGTCGTCTACCAGATC
GAAGGCAGCAAAGCCGTGCCCTGGGTGATTCTGTCCGACGGCGACGGCACCGTGGAGAAA
GGCTTCAAGGCCGAATGGCTGGCAGTGAAGGACGAGCGTCTGTACGTGGGCGGCCTGGGC
AAGGAGTGGACGACCACTACGGGTGATGTGGTGAACGAGAACCCGGAGTGGGTGAAGGTG
GTGGGCTACAAGGGCAGCGTGGACCACGAGAACTGGGTGTCCAACTACAACGCCCTGCGG
GCTGCTGCCGGCATCCAGCCGCCAGGCTACCTCATCCATGAGTCTGCCTGCTGGAGTGAC
ACGCTGCAGCGCTGGTTCTTCCTGCCGCGCCGCGCCAGCCAGGAGCGCTACAGCGAGAAG
GACGACGAGCGCAAGGGCGCCAACCTGCTGCTGAGCGCCTCCCCTGACTTCGGCGACATC
GCTGTGAGCCACGTCGGGGCGGTGGTCCCCACTCACGGCTTCTCGTCCTTCAAGTTCATC
CCCAACACCGACGACCAGATCATTGTGGCCCTCAAATCCGAGGAGGACAGCGGCAGAGTC
GCCTCCTACATCATGGCCTTCACGCTGGACGGGCGCTTCCTGTTGCCGGAGACCAAGATC
GGAAGCGTGAAATACGAAGGCATCGAGTTCATTTAA

# Drug_Target_3_General_Function:
Involved in calcium ion binding

# Drug_Target_3_General_References:
12167635	Failer BU, Braun N, Zimmermann H: Cloning, expression, and functional characterization of a Ca(2+)-dependent endoplasmic reticulum nucleoside diphosphatase. J Biol Chem. 2002 Oct 4;277(40):36978-86. Epub 2002 Aug 6.
12234496	Smith TM, Hicks-Berger CA, Kim S, Kirley TL: Cloning, expression, and characterization of a soluble calcium-activated nucleotidase, a human enzyme belonging to a new family of extracellular nucleotidases. Arch Biochem Biophys. 2002 Oct 1;406(1):105-15.
12761501	Matsuda A, Suzuki Y, Honda G, Muramatsu S, Matsuzaki O, Nagano Y, Doi T, Shimotohno K, Harada T, Nishida E, Hayashi H, Sugano S: Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene. 2003 May 22;22(21):3307-18.

# Drug_Target_3_HGNC_ID:
HGNC:19721

# Drug_Target_3_HPRD_ID:
13003

# Drug_Target_3_ID:
3186

# Drug_Target_3_Locus:
17q25.3

# Drug_Target_3_Molecular_Weight:
44840

# Drug_Target_3_Name:
Soluble calcium-activated nucleotidase 1

# Drug_Target_3_Number_of_Residues:
401

# Drug_Target_3_PDB_ID:
1S1D

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF06079	Apyrase

# Drug_Target_3_Protein_Sequence:
>Soluble calcium-activated nucleotidase 1
MPVQLSEHPEWNESMHSLRISVGGLPVLASMTKAADPRFRPRWKVILTFFVGAAILWLLC
SHRPAPGRPPTHNAHNWRLGQAPANWYNDTYPLSPPQRTPAGIRYRIAVIADLDTESRAQ
EENTWFSYLKKGYLTLSDSGDKVAVEWDKDHGVLESHLAEKGRGMELSDLIVFNGKLYSV
DDRTGVVYQIEGSKAVPWVILSDGDGTVEKGFKAEWLAVKDERLYVGGLGKEWTTTTGDV
VNENPEWVKVVGYKGSVDHENWVSNYNALRAAAGIQPPGYLIHESACWSDTLQRWFFLPR
RASQERYSEKDDERKGANLLLSASPDFGDIAVSHVGAVVPTHGFSSFKFIPNTDDQIIVA
LKSEEDSGRVASYIMAFTLDGRFLLPETKIGSVKYEGIEFI

# Drug_Target_3_Reaction:
a nucleoside diphosphate + H2O = a nucleotide + phosphate

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Calcium-dependent nucleotidase with a preference for UDP. The order of activity with different substrates is UDP > GDP > UTP > GTP. Has very low activity towards ADP and even lower activity towards ATP. Does not hydrolyze AMP and GMP

# Drug_Target_3_SwissProt_ID:
Q8WVQ1

# Drug_Target_3_SwissProt_Name:
CANT1_HUMAN

# Drug_Target_3_Synonyms:
Apyrase homolog
EC 3.6.1.6
Putative MAPK-activating protein PM09
Putative NF-kappa-B-activating protein 107
SCAN-1

# Drug_Target_3_Theoretical_pI:
5.98

# Drug_Target_3_Transmembrane_Regions:
45-62

# Drug_Target_4_Cellular_Location:
Cell membrane
lipid-anchor

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
U18997

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
nlpI

# Drug_Target_4_Gene_Sequence:
Not Available

# Drug_Target_4_General_Function:
Not Available

# Drug_Target_4_General_References:
10400590	Ohara M, Wu HC, Sankaran K, Rick PD: Identification and characterization of a new lipoprotein, NlpI, in Escherichia coli K-12. J Bacteriol. 1999 Jul;181(14):4318-25.
2045359	Toone WM, Rudd KE, Friesen JD: deaD, a new Escherichia coli gene encoding a presumed ATP-dependent RNA helicase, can suppress a mutation in rpsB, the gene encoding ribosomal protein S2. J Bacteriol. 1991 Jun;173(11):3291-302.
2432069	Regnier P, Grunberg-Manago M, Portier C: Nucleotide sequence of the pnp gene of Escherichia coli encoding polynucleotide phosphorylase. Homology of the primary structure of the protein with the RNA-binding domain of ribosomal protein S1. J Biol Chem. 1987 Jan 5;262(1):63-8.
7984428	Borodovsky M, Rudd KE, Koonin EV: Intrinsic and extrinsic approaches for detecting genes in a bacterial genome. Nucleic Acids Res. 1994 Nov 11;22(22):4756-67.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3780

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
33621

# Drug_Target_4_Name:
Lipoprotein nlpI precursor

# Drug_Target_4_Number_of_Residues:
294

# Drug_Target_4_PDB_ID:
1XNF

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00515	TPR_1

# Drug_Target_4_Protein_Sequence:
>Lipoprotein nlpI precursor
MKPFLRWCFVATALTLAGCSNTSWRKSEVLAVPLQPTLQQEVILARMEQILASRALTDDE
RAQLLYERGVLYDSLGLRALARNDFSQALAIRPDMPEVFNYLGIYLTQAGNFDAAYEAFD
SVLELDPTYNYAHLNRGIALYYGGRDKLAQDDLLAFYQDDPNDPFRSLWLYLAEQKLDEK
QAKEVLKQHFEKSDKEQWGWNIVEFYLGNISEQTLMERLKADATDNTSLAEHLSETNFYL
GKYYLSLGDLDSATALFKLAVANNVHNFVEHRYALLELSLLGQDQDDLAESDQQ

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
1-18

# Drug_Target_4_Specific_Function:
May be involved in cell division. Overexpression of nlpI results in the loss of the rod morphology and the formation of single prolate ellipsoids and pairs of prolate ellipsoids joined by partial constrictions

# Drug_Target_4_SwissProt_ID:
P0AFB1

# Drug_Target_4_SwissProt_Name:
NLPI_ECOLI

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
4.35

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
Not Available

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
AE007869

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
dps

# Drug_Target_5_Gene_Sequence:
>489 bp
ATGAAGACGCACAAGACGAAGAACGACCTGCCTTCCAACGCCAAGTCGACCGTGATCGGC
ATTCTGAACGAATCTCTCGCCTCGGTGATCGATCTCGCGCTTGTCACCAAGCAGGCGCAC
TGGAACCTGAAAGGCCCGCAATTCATCGCCGTCCACGAACTTCTCGACACCTTCCGCACC
CAGCTCGACAATCACGGCGATACGATTGCCGAACGCGTCGTGCAGCTGGGCGGCACCGCA
CTCGGCAGCCTGCAAGCCGTCTCCTCGACGACGAAGCTCAAGGCCTATCCGACCGATATC
TATAAAATCCACGATCATCTCGACGCTCTGATCGAGCGTTATGGCGAAGTCGCCAACATG
ATCCGCAAGGCGATCGACGATTCCGACGAAGCCGGCGATCCGACGACGGCCGATATCTTC
ACCGCCGCCTCGCGCGATCTCGACAAGTCACTGTGGTTCCTCGAAGCCCATGTGCAGGAA
AAGAGCTGA

# Drug_Target_5_General_Function:
Involved in oxidoreductase activity

# Drug_Target_5_General_References:
11743193	Wood DW, Setubal JC, Kaul R, Monks DE, Kitajima JP, Okura VK, Zhou Y, Chen L, Wood GE, Almeida NF Jr, Woo L, Chen Y, Paulsen IT, Eisen JA, Karp PD, Bovee D Sr, Chapman P, Clendenning J, Deatherage G, Gillet W, Grant C, Kutyavin T, Levy R, Li MJ, McClelland E, Palmieri A, Raymond C, Rouse G, Saenphimmachak C, Wu Z, Romero P, Gordon D, Zhang S, Yoo H, Tao Y, Biddle P, Jung M, Krespan W, Perry M, Gordon-Kamm B, Liao L, Kim S, Hendrick C, Zhao ZY, Dolan M, Chumley F, Tingey SV, Tomb JF, Gordon MP, Olson MV, Nester EW: The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science. 2001 Dec 14;294(5550):2317-23.
11743194	Goodner B, Hinkle G, Gattung S, Miller N, Blanchard M, Qurollo B, Goldman BS, Cao Y, Askenazi M, Halling C, Mullin L, Houmiel K, Gordon J, Vaudin M, Iartchouk O, Epp A, Liu F, Wollam C, Allinger M, Doughty D, Scott C, Lappas C, Markelz B, Flanagan C, Crowell C, Gurson J, Lomo C, Sear C, Strub G, Cielo C, Slater S: Genome sequence of the plant pathogen and biotechnology agent Agrobacterium tumefaciens C58. Science. 2001 Dec 14;294(5550):2323-8.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
4411

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
17823

# Drug_Target_5_Name:
DNA protection during starvation protein

# Drug_Target_5_Number_of_Residues:
162

# Drug_Target_5_PDB_ID:
1O9R

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00210	Ferritin

# Drug_Target_5_Protein_Sequence:
>DNA protection during starvation protein
MKTHKTKNDLPSNAKSTVIGILNESLASVIDLALVTKQAHWNLKGPQFIAVHELLDTFRT
QLDNHGDTIAERVVQLGGTALGSLQAVSSTTKLKAYPTDIYKIHDHLDALIERYGEVANM
IRKAIDDSDEAGDPTTADIFTAASRDLDKSLWFLEAHVQEKS

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Protects DNA from oxidative damage by sequestering intracellular Fe(2+) ion and storing it in the form of Fe(3+) oxyhydroxide mineral, which can be released after reduction. It efficiently inhibits hydroxyl radical production by the Fenton reaction. Does not bind DNA

# Drug_Target_5_SwissProt_ID:
Q8UCK6

# Drug_Target_5_SwissProt_Name:
DPS_AGRT5

# Drug_Target_5_Synonyms:
EC 1.16.-.-

# Drug_Target_5_Theoretical_pI:
5.86

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
Not Available

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
L42023

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
HI_1317

# Drug_Target_6_Gene_Sequence:
>816 bp
ATGAAAACAACATTACTAAAAACACTGACACCAGAGCTTCATCTTGTTCAACATAACGAC
ATTCCAGTTCCTTCACTTAAAACATGCGGTTGGAACACCAAAAATTTCCCCTGCAAGGGG
CACAGCTTATCAGTTGGAANCCCCCAAAATGCGAAGCAAGATGTATTATGGCTAAGTGAA
GTAGAGCCATTCAAAAATGGCAATGCTATTCGTGGTGGTGTACCGATTTGTTATCCTTGG
TTTGGTGGCGTAAAACAACCTGCGCACGGTACAGCTCGTATTCGTTTATGGCAGTTGAGT
CATTACTATATTTCAGTGCATAAAGTGCGGTTAGAATTTGAGTTGTTTTCTGATTTAAAT
ATTATCGAAGCTAAAGTCTCAATGGTATTTACAGATAAATGTCATTTAACTTTTACCCAT
TATGGCGAAGAATCAGCCCAAGCAGCATTACATACCTATTTTAATATTGGGGATATTAAT
CAAGTGGAAGTACAAGGTTTACCTGAAACTTGTTTTAATAGCTTAAACCAACAACAAGAA
AATGTTCCGTCACCGCGTCACATTTCTGAAAATGTTGATTGCATTTATTCTGCAGAAAAC
ATGCAGAATCAAATCCTAGATAAAAGTTTCAATCGTACAATTGCACTGCATCATCATAAT
GCAAGCCAATTTGTTCTTTGGAATCCTTGGCACAAAAAGACGAGTGGAATGAGTGAAACT
GGCTATCAAAAGATGTTGTGCTTAGAAACTGCACGTATCCATCACTTGCTTGAATTTGGC
GAAAGTTTAAGCGTAGAAATTTCGCTTAAAGGCTAA

# Drug_Target_6_General_Function:
Involved in isomerase activity

# Drug_Target_6_General_References:
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
5423

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
30748

# Drug_Target_6_Name:
UPF0010 protein HI1317

# Drug_Target_6_Number_of_Residues:
271

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF01263	Aldose_epim

# Drug_Target_6_Protein_Sequence:
>UPF0010 protein HI1317
MKTTLLKTLTPELHLVQHNDIPVPSLKTCGWNTKNFPCKGHSLSVGXPQNAKQDVLWLSE
VEPFKNGNAIRGGVPICYPWFGGVKQPAHGTARIRLWQLSHYYISVHKVRLEFELFSDLN
IIEAKVSMVFTDKCHLTFTHYGEESAQAALHTYFNIGDINQVEVQGLPETCFNSLNQQQE
NVPSPRHISENVDCIYSAENMQNQILDKSFNRTIALHHHNASQFVLWNPWHKKTSGMSET
GYQKMLCLETARIHHLLEFGESLSVEISLKG

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
P44160

# Drug_Target_6_SwissProt_Name:
Y1317_HAEIN

# Drug_Target_6_Synonyms:
Not Available

# Drug_Target_6_Theoretical_pI:
7.25

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Nucleus

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
Not Available

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
NEIL1

# Drug_Target_7_GenBank_ID_Gene:
AB079068

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
NEIL1

# Drug_Target_7_Gene_Sequence:
>1173 bp
ATGCCTGAGGGCCCCGAGCTGCACCTGGCCAGCCAGTTTGTGAATGAGGCCTGCAGGGCG
CTGGTGTTCGGCGGCTGCGTGGAGAAGTCCTCTGTCAGCCGCAACCCTGAGGTGCCCTTT
GAGAGCAGTGCCTACCGCATCTCAGCTTCAGCCCGCGGCAAGGAGCTGCGCCTGATACTG
AGCCCTCTGCCTGGGGCCCAGCCCCAACAGGAGCCACTGGCCCTGGTCTTCCGCTTCGGC
ATGTCCGGCTCTTTTCAGCTGGTGCCCCGCGAGGAGCTGCCACGCCATGCCCACCTGCGC
TTTTACACGGCCCCGCCTGGCCCCCGGCTCGCCCTATGTTTCGTGGACATCCGCCGGTTC
GGCCGCTGGGACCTTGGGGGAAAGTGGCAGCCGGGCCGCGGGCCCTGTGTCTTGCAGGAG
TACCAGCAGTTCAGGGAGAATGTGCTACGAAACCTAGCGGATAAGGCCTTTGACCGGCCC
ATCTGCGAGGCCCTCCTGGACCAGAGGTTCTTCAATGGCATTGGCAACTATCTGCGGGCA
GAGATCCTGTACCGGCTGAAGATCCCCCCCTTTGAGAAGGCCCGCTCGGTCCTGGAGGCC
CTGCAGCAGCACAGGCCGAGCCCGGAGCTGACCCTGAGCCAGAAGATAAGGACCAAGCTG
CAGAATCCAGACCTGCTGGAGCTATGTCACTCAGTGCCCAAGGAAGTGGTCCAGTTGGGG
GGCAGGGGCTACGGGTCAGAGAGCGGGGAGGAGGACTTTGCTGCCTTTCGAGCCTGGCTG
CGCTGCTATGGCATGCCAGGCATGAGCTCCCTGCAGGACCGGCATGGCCGTACCATCTGG
TTCCAGGGGGATCCTGGACCGTTGGCACCCAAAGGGCGCAAGTCCCGCAAAAAGAAATCC
AAGGCCACACAGCTGAGTCCTGAGGACAGAGTGGAGGACGCTTTGCCTCCAAGCAAGGCC
CCTTCCAGGACACGAAGGGCAAAGAGAGACCTTCCTAAGAGGACTGCAACCCAGCGGCCT
GAGGGGACCAGCCTCCAGCAGGACCCAGAAGCTCCCACAGTGCCCAAGAAGGGGAGGAGG
AAGGGGCGACAGGCAGCCTCTGGCCACTGCAGACCCCGGAAGGTCAAGGCTGACATCCCA
TCCTTGGAACCAGAGGGGACCTCAGCCTCTTAG

# Drug_Target_7_General_Function:
Involved in damaged DNA binding

# Drug_Target_7_General_References:
12200441	Takao M, Kanno S, Kobayashi K, Zhang QM, Yonei S, van der Horst GT, Yasui A: A back-up glycosylase in Nth1 knock-out mice is a functional Nei (endonuclease VIII) homologue. J Biol Chem. 2002 Nov 1;277(44):42205-13. Epub 2002 Aug 27.

# Drug_Target_7_HGNC_ID:
HGNC:18448

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
5424

# Drug_Target_7_Locus:
15q24.2

# Drug_Target_7_Molecular_Weight:
43685

# Drug_Target_7_Name:
Endonuclease VIII-like 1

# Drug_Target_7_Number_of_Residues:
390

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF01149	Fapy_DNA_glyco
PF06831	H2TH
PF09292	Neil1-DNA_bind

# Drug_Target_7_Protein_Sequence:
>Endonuclease VIII-like 1
MPEGPELHLASQFVNEACRALVFGGCVEKSSVSRNPEVPFESSAYRISASARGKELRLIL
SPLPGAQPQQEPLALVFRFGMSGSFQLVPREELPRHAHLRFYTAPPGPRLALCFVDIRRF
GRWDLGGKWQPGRGPCVLQEYQQFRENVLRNLADKAFDRPICEALLDQRFFNGIGNYLRA
EILYRLKIPPFEKARSVLEALQQHRPSPELTLSQKIRTKLQNPDLLELCHSVPKEVVQLG
GKGYGSESGEEDFAAFRAWLRCYGMPGMSSLQDRHGRTIWFQGDPGPLAPKGRKSRKKKS
KATQLSPEDRVEDALPPSKAPSRTRRAKRDLPKRTATQRPEGTSLQQDPEAPTVPKKGRR
KGRQAASGHCRPRKVKADIPSLEPEGTSAS

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Involved in base excision repair of DNA damaged by oxidation or by mutagenic agents. Acts as DNA glycosylase that recognizes and removes damaged bases. Has a preference for oxidized pyrimidines, such as thymine glycol, formamidopyrimidine (Fapy) and 5-hydroxyuracil. Has marginal activity towards 8- oxoguanine. Has AP (apurinic/apyrimidinic) lyase activity and introduces nicks in the DNA strand. Cleaves the DNA backbone by beta-delta elimination to generate a single-strand break at the site of the removed base with both 3'- and 5'-phosphates. Has DNA glycosylase/lyase activity towards mismatched uracil and thymine, in particular in U:C and T:C mismatches

# Drug_Target_7_SwissProt_ID:
Q96FI4

# Drug_Target_7_SwissProt_Name:
NEIL1_HUMAN

# Drug_Target_7_Synonyms:
DNA glycosylase/AP lyase Neil1
DNA-(apurinic or apyrimidinic site) lyase Neil1
EC 3.2.2.-
EC 4.2.99.18
FPG1
NEH1
Nei-like 1

# Drug_Target_7_Theoretical_pI:
10.54

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
X00171

# Drug_Target_8_GenBank_ID_Protein:
48348

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
ctxB

# Drug_Target_8_Gene_Sequence:
>375 bp
ATGATTAAATTAAAATTTGGTGTTTTTTTTACAGTTTTACTATCTTCAGCATATGCACAT
GGAACACCTCAAAATATTACTGATTTGTGTGCAGAATCACACAACACACAAATATATACG
CTAAATGATAAGATATTTTCGTATACAGAATCTCTAGCTGGAAAAAGAGAGATGGCTATC
ATTACTTTTAAGAATGGTGCAATTTTTCAAGTAGAAGTACCAAGTAGTCAACATATAGAT
TCACAAAAAAAAGCGATTGAAAGGATGAAGGATACCCTGAGGATTGCATATCTTACTGAA
GCTAAAGTCGAAAAGTTATGTGTATGGAATAATAAAACGCCTCATGCGATTGCCGCAATT
AGTATGGCAAATTAA

# Drug_Target_8_General_Function:
Not Available

# Drug_Target_8_General_References:
10952301	Heidelberg JF, Eisen JA, Nelson WC, Clayton RA, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Umayam L, Gill SR, Nelson KE, Read TD, Tettelin H, Richardson D, Ermolaeva MD, Vamathevan J, Bass S, Qin H, Dragoi I, Sellers P, McDonald L, Utterback T, Fleishmann RD, Nierman WC, White O, Salzberg SL, Smith HO, Colwell RR, Mekalanos JJ, Venter JC, Fraser CM: DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature. 2000 Aug 3;406(6795):477-83.
11447291	Aman AT, Fraser S, Merritt EA, Rodigherio C, Kenny M, Ahn M, Hol WG, Williams NA, Lencer WI, Hirst TR: A mutant cholera toxin B subunit that binds GM1- ganglioside but lacks immunomodulatory or toxic activity. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8536-41. Epub 2001 Jul 10.
11880036	Pickens JC, Merritt EA, Ahn M, Verlinde CL, Hol WG, Fan E: Anchor-based design of improved cholera toxin and E. coli heat-labile enterotoxin receptor binding antagonists that display multiple binding modes. Chem Biol. 2002 Feb;9(2):215-24.
12405825	Zhang Z, Merritt EA, Ahn M, Roach C, Hou Z, Verlinde CL, Hol WG, Fan E: Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin. J Am Chem Soc. 2002 Nov 6;124(44):12991-8.
13679513	Fujinaga Y, Wolf AA, Rodighiero C, Wheeler H, Tsai B, Allen L, Jobling MG, Rapoport T, Holmes RK, Lencer WI: Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulm. Mol Biol Cell. 2003 Dec;14(12):4783-93. Epub 2003 Sep 17.
3214	Gill DM: The arrangement of subunits in cholera toxin. Biochemistry. 1976 Mar 23;15(6):1242-8.
6315707	Lockman H, Kaper JB: Nucleotide sequence analysis of the A2 and B subunits of Vibrio cholerae enterotoxin. J Biol Chem. 1983 Nov 25;258(22):13722-6.
6646234	Mekalanos JJ, Swartz DJ, Pearson GD, Harford N, Groyne F, de Wilde M: Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature. 1983 Dec 8-14;306(5943):551-7.
7658472	Zhang RG, Westbrook ML, Westbrook EM, Scott DL, Otwinowski Z, Maulik PR, Reed RA, Shipley GG: The 2.4 A crystal structure of cholera toxin B subunit pentamer: choleragenoid. J Mol Biol. 1995 Aug 25;251(4):550-62.
8003954	Merritt EA, Sarfaty S, van den Akker F, L'Hoir C, Martial JA, Hol WG: Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 1994 Feb;3(2):166-75.
8181723	Lebens M, Holmgren J: Structure and arrangement of the cholera toxin genes in Vibrio cholerae O139. FEMS Microbiol Lett. 1994 Apr 1;117(2):197-202.
903362	Lai CY: Determination of the primary structure of cholera toxin B subunit. J Biol Chem. 1977 Oct 25;252(20):7249-56.
903363	Kurosky A, Markel DE, Peterson JW: Covalent structure of the beta chain of cholera enterotoxin. J Biol Chem. 1977 Oct 25;252(20):7257-64.
9232653	Merritt EA, Sarfaty S, Jobling MG, Chang T, Holmes RK, Hirst TR, Hol WG: Structural studies of receptor binding by cholera toxin mutants. Protein Sci. 1997 Jul;6(7):1516-28.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
2723

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
13957

# Drug_Target_8_Name:
Cholera enterotoxin subunit B

# Drug_Target_8_Number_of_Residues:
124

# Drug_Target_8_PDB_ID:
1S5F

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF01376	Enterotoxin_b

# Drug_Target_8_Protein_Sequence:
>Cholera enterotoxin subunit B precursor
MIKLKFGVFFTVLLSSAYAHGTPQNITDLCAEYHNTQIYTLNDKIFSYTESLAGKREMAI
ITFKNGAIFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNNKTPHAIAAI
SMAN

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
1-21

# Drug_Target_8_Specific_Function:
The B subunit pentameric ring directs the A subunit to its target by binding to the GM1 gangliosides present on the surface of the intestinal epithelial cells. It can bind five GM1 gangliosides. It has no toxic activity by itself

# Drug_Target_8_SwissProt_ID:
P01556

# Drug_Target_8_SwissProt_Name:
CHTB_VIBCH

# Drug_Target_8_Synonyms:
Cholera enterotoxin B chain
Cholera enterotoxin gamma chain
Cholera enterotoxin subunit B precursor
Choleragenoid

# Drug_Target_8_Theoretical_pI:
9.09

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
AMD1

# Drug_Target_9_GenBank_ID_Gene:
M21154

# Drug_Target_9_GenBank_ID_Protein:
178518

# Drug_Target_9_GeneCard_ID:
AMD1

# Drug_Target_9_Gene_Name:
AMD1

# Drug_Target_9_Gene_Sequence:
>1005 bp
ATGGAAGCTGCACATTTTTTCGAAGGGACCGAGAAGCTGCTGGAGGTTTGGTTCTCCCGG
CAGCAGCCCGACGCAAACCAAGGATCTGGGGATCTTCGCACTATCCCAAGATCTGAGTGG
GACATACTTTTGAAGGATGTGCAATGTTCAATCATAAGTGTGACAAAAACTGACAAGCAG
GAAGCTTATGTACTCAGTGAGAGTAGCATGTTTGTCTCCAAGAGACGTTTCATTTTGAAG
ACATGTGGTACCACCCTCTTGCTGAAAGCACTGGTTCCCCTGTTGAAGCTTGCTAGGGAT
TACAGTGGGTTTGACTCAATTCAAAGCTTCTTTTATTCTCGTAAGAATTTCATGAAGCCT
TCTCACCAAGGGTACCCACACCGGAATTTCCAGGAAGAAATAGAGTTTCTTAATGCAATT
TTCCCAAATGGAGCAGGATATTGTATGGGACGTATGAATTCTGACTGTTGGTACTTATAT
ACTCTGGATTTCCCAGAGAGTCGGGTAATCAGTCAGCCAGATCAAACCTTGGAAATTCTG
ATGAGTGAGCTTGACCCAGCAGTTATGGACCAGTTCTACATGAAAGATGGTGTTACTGCA
AAGGATGTCACTCGTGAGAGTGGAATTCGTGACCTGATACCAGGTTCTGTCATTGATGCC
ACAATGTTCAATCCTTGTGGGTATTCGATGAATGGAATGAAATCGGATGGAACTTATTGG
ACTATTCACATCACTCCAGAACCAGAATTTTCTTATGTTAGCTTTGAAACAAACTTAAGT
CAGACCTCCTATGATGACCTGATCAGGAAAGTTGTAGAAGTCTTCAAGCCAGGAAAATTT
GTGACCACCTTGTTTGTTAATCAGAGTTCTAAATGTCGCACAGTGCTTGCTTCGCCCCAG
AAGATTGAAGGTTTTAAGCGTCTTGATTGCCAGAGTGCTATGTTCAATGATTACAATTTT
GTTTTTACCAGTTTTGCTAAGAAGCAGCAACAACAGCAGAGTTGA

# Drug_Target_9_General_Function:
Involved in adenosylmethionine decarboxylase activity

# Drug_Target_9_General_References:
10029540	Xiong H, Stanley BA, Pegg AE: Role of cysteine-82 in the catalytic mechanism of human S-adenosylmethionine decarboxylase. Biochemistry. 1999 Feb 23;38(8):2462-70.
10378277	Ekstrom JL, Mathews II, Stanley BA, Pegg AE, Ealick SE: The crystal structure of human S-adenosylmethionine decarboxylase at 2.25 A resolution reveals a novel fold. Structure. 1999 May;7(5):583-95.
10574985	Xiong H, Pegg AE: Mechanistic studies of the processing of human S-adenosylmethionine decarboxylase proenzyme. Isolation of an ester intermediate. J Biol Chem. 1999 Dec 3;274(49):35059-66.
11583147	Tolbert WD, Ekstrom JL, Mathews II, Secrist JA 3rd, Kapoor P, Pegg AE, Ealick SE: The structural basis for substrate specificity and inhibition of human S-adenosylmethionine decarboxylase. Biochemistry. 2001 Aug 14;40(32):9484-94.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
1917972	Stanley BA, Pegg AE: Amino acid residues necessary for putrescine stimulation of human S-adenosylmethionine decarboxylase proenzyme processing and catalytic activity. J Biol Chem. 1991 Oct 5;266(28):18502-6.
2460457	Pajunen A, Crozat A, Janne OA, Ihalainen R, Laitinen PH, Stanley B, Madhubala R, Pegg AE: Structure and regulation of mammalian S-adenosylmethionine decarboxylase. J Biol Chem. 1988 Nov 15;263(32):17040-9.

# Drug_Target_9_HGNC_ID:
HGNC:457

# Drug_Target_9_HPRD_ID:
01622

# Drug_Target_9_ID:
113

# Drug_Target_9_Locus:
6q21-q22

# Drug_Target_9_Molecular_Weight:
38340

# Drug_Target_9_Name:
S-adenosylmethionine decarboxylase proenzyme

# Drug_Target_9_Number_of_Residues:
334

# Drug_Target_9_PDB_ID:
1MSV

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF01536	SAM_decarbox

# Drug_Target_9_Protein_Sequence:
>S-adenosylmethionine decarboxylase proenzyme
MEAAHFFEGTEKLLEVWFSRQQPDANQGSGDLRTIPRSEWDILLKDVQCSIISVTKTDKQ
EAYVLSESSMFVSKRRFILKTCGTTLLLKALVPLLKLARDYSGFDSIQSFFYSRKNFMKP
SHQGYPHRNFQEEIEFLNAIFPNGAAYCMGRMNSDCWYLYTLDFPESRVISQPDQTLEIL
MSELDPAVMDQFYMKDGVTAKDVTRESGIRDLIPGSVIDATMFNPCGYSMNGMKSDGTYW
TIHITPEPEFSYVSFETNLSQTSYDDLIRKVVEVFKPGKFVTTLFVNQSSKCRTVLASPQ
KIEGFKRLDCQSAMFNDYNFVFTSFAKKQQQQQS

# Drug_Target_9_Reaction:
S-adenosyl-L-methionine = (5-deoxy-5-adenosyl)(3-aminopropyl)methylsulfonium salt + CO2

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Not Available

# Drug_Target_9_SwissProt_ID:
P17707

# Drug_Target_9_SwissProt_Name:
DCAM_HUMAN

# Drug_Target_9_Synonyms:
AdoMetDC
EC 4.1.1.50
SamDC

# Drug_Target_9_Theoretical_pI:
5.78

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB03754
